Reports Q3 revenue $83.04M, consensus $71.14M. “We delivered a strong third quarter, generating $83 million in revenue and 26,841 in total test report volume,” said Derek Maetzold, president and chief executive officer of Castle Biosciences (CSTL). “These strong results are a testament to the workforce culture we have built at Castle and our unwavering commitment to improving patient care.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL: